Maladie du greffon contre l'hôte : Questions médicales fréquentes
Nom anglais: Graft vs Host Disease
Descriptor UI:D006086
Tree Number:C20.452
Termes MeSH sélectionnés :
Tissue Array Analysis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Maladie du greffon contre l'hôte : Questions médicales les plus fréquentes",
"headline": "Maladie du greffon contre l'hôte : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Maladie du greffon contre l'hôte : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-17",
"dateModified": "2025-02-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Maladie du greffon contre l'hôte"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladies du système immunitaire",
"url": "https://questionsmedicales.fr/mesh/D007154",
"about": {
"@type": "MedicalCondition",
"name": "Maladies du système immunitaire",
"code": {
"@type": "MedicalCode",
"code": "D007154",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Syndrome de bronchiolite oblitérante",
"alternateName": "Bronchiolitis Obliterans Syndrome",
"url": "https://questionsmedicales.fr/mesh/D000092122",
"about": {
"@type": "MedicalCondition",
"name": "Syndrome de bronchiolite oblitérante",
"code": {
"@type": "MedicalCode",
"code": "D000092122",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.452.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Maladie du greffon contre l'hôte",
"alternateName": "Graft vs Host Disease",
"code": {
"@type": "MedicalCode",
"code": "D006086",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Stephanie J Lee",
"url": "https://questionsmedicales.fr/author/Stephanie%20J%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."
}
},
{
"@type": "Person",
"name": "Betty K Hamilton",
"url": "https://questionsmedicales.fr/author/Betty%20K%20Hamilton",
"affiliation": {
"@type": "Organization",
"name": "Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States of America."
}
},
{
"@type": "Person",
"name": "Najla El Jurdi",
"url": "https://questionsmedicales.fr/author/Najla%20El%20Jurdi",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis."
}
},
{
"@type": "Person",
"name": "Steven Z Pavletic",
"url": "https://questionsmedicales.fr/author/Steven%20Z%20Pavletic",
"affiliation": {
"@type": "Organization",
"name": "National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, United States of America."
}
},
{
"@type": "Person",
"name": "Anthony D Sung",
"url": "https://questionsmedicales.fr/author/Anthony%20D%20Sung",
"affiliation": {
"@type": "Organization",
"name": "Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Tissue microarray analyses of the essential DNA repair factors ATM, DNA-PKcs and Ku80 in head and neck squamous cell carcinoma.",
"datePublished": "2024-10-30",
"url": "https://questionsmedicales.fr/article/39478631",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13014-024-02541-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "EBV-Associated Gastric Cancer; An In Situ Hybridization Assay on Tissue Microarray: A Multi-Region Study from Four Major Provinces of Iran.",
"datePublished": "2024-04-01",
"url": "https://questionsmedicales.fr/article/38685845",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.34172/aim.2024.28"
}
},
{
"@type": "ScholarlyArticle",
"name": "An Automation Workflow for High-Throughput Manufacturing and Analysis of Scaffold-Supported 3D Tissue Arrays.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37086259",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/adhm.202202422"
}
},
{
"@type": "ScholarlyArticle",
"name": "Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets.",
"datePublished": "2023-09-11",
"url": "https://questionsmedicales.fr/article/37697694",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cjp2.342"
}
},
{
"@type": "ScholarlyArticle",
"name": "DNA quality evaluation of formalin-fixed paraffin-embedded heart tissue for DNA methylation array analysis.",
"datePublished": "2023-02-03",
"url": "https://questionsmedicales.fr/article/36737451",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-29120-y"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladie du greffon contre l'hôte",
"item": "https://questionsmedicales.fr/mesh/D006086"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Maladie du greffon contre l'hôte - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Maladie du greffon contre l'hôte",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Maladie du greffon contre l'hôte",
"description": "Comment diagnostiquer la GVHD ?\nQuels tests sont utilisés pour la GVHD ?\nQuels signes cliniques indiquent la GVHD ?\nLa GVHD peut-elle être confondue avec d'autres maladies ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tissue+Array+Analysis&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Maladie du greffon contre l'hôte",
"description": "Quels sont les symptômes cutanés de la GVHD ?\nLa GVHD affecte-t-elle le système digestif ?\nQuels symptômes hépatiques sont associés à la GVHD ?\nLa GVHD peut-elle causer des problèmes oculaires ?\nQuels symptômes respiratoires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tissue+Array+Analysis&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Maladie du greffon contre l'hôte",
"description": "Comment prévenir la GVHD après une greffe ?\nLe choix du donneur influence-t-il la GVHD ?\nLes traitements préventifs sont-ils efficaces ?\nLes greffes de cellules souches de sang de cordon sont-elles plus sûres ?\nLes soins post-greffe aident-ils à prévenir la GVHD ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tissue+Array+Analysis&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Maladie du greffon contre l'hôte",
"description": "Quels traitements sont utilisés pour la GVHD ?\nLa photothérapie est-elle efficace contre la GVHD ?\nLes greffes de cellules souches peuvent-elles aider ?\nQuels médicaments sont prescrits pour la GVHD ?\nLa thérapie cellulaire est-elle une option ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tissue+Array+Analysis&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Maladie du greffon contre l'hôte",
"description": "Quelles sont les complications de la GVHD ?\nLa GVHD peut-elle entraîner des infections ?\nQuels cancers peuvent survenir après la GVHD ?\nLa GVHD peut-elle affecter la qualité de vie ?\nComment gérer les complications de la GVHD ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tissue+Array+Analysis&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Maladie du greffon contre l'hôte",
"description": "Quels sont les principaux facteurs de risque de la GVHD ?\nL'âge influence-t-il le risque de GVHD ?\nLe sexe du receveur joue-t-il un rôle ?\nLes antécédents médicaux augmentent-ils le risque ?\nLa source de greffe influence-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tissue+Array+Analysis&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la GVHD ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et des biopsies cutanées ou intestinales."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la GVHD ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des biopsies sont effectués pour évaluer l'atteinte des organes."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent la GVHD ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent éruptions cutanées, diarrhée, et atteinte hépatique."
}
},
{
"@type": "Question",
"name": "La GVHD peut-elle être confondue avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec des infections ou d'autres maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique de greffe et les traitements antérieurs sont cruciaux pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes cutanés de la GVHD ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des éruptions, des démangeaisons et des desquamations."
}
},
{
"@type": "Question",
"name": "La GVHD affecte-t-elle le système digestif ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des diarrhées, des douleurs abdominales et des nausées."
}
},
{
"@type": "Question",
"name": "Quels symptômes hépatiques sont associés à la GVHD ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent jaunisse, fatigue et élévation des enzymes hépatiques."
}
},
{
"@type": "Question",
"name": "La GVHD peut-elle causer des problèmes oculaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner sécheresse oculaire et inflammation conjonctivale."
}
},
{
"@type": "Question",
"name": "Quels symptômes respiratoires peuvent survenir ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la toux, l'essoufflement et des infections pulmonaires peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment prévenir la GVHD après une greffe ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'utilisation d'immunosuppresseurs et le choix de donneurs compatibles."
}
},
{
"@type": "Question",
"name": "Le choix du donneur influence-t-il la GVHD ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un donneur HLA compatible réduit le risque de GVHD."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils efficaces ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements préventifs diminuent significativement l'incidence de la GVHD."
}
},
{
"@type": "Question",
"name": "Les greffes de cellules souches de sang de cordon sont-elles plus sûres ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent présenter un risque réduit de GVHD par rapport aux greffes de moelle osseuse."
}
},
{
"@type": "Question",
"name": "Les soins post-greffe aident-ils à prévenir la GVHD ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical rigoureux et des soins appropriés sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels traitements sont utilisés pour la GVHD ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "La photothérapie est-elle efficace contre la GVHD ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la photothérapie peut être utilisée pour traiter les éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Les greffes de cellules souches peuvent-elles aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des greffes supplémentaires peuvent être envisagées dans certains cas de GVHD sévère."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont prescrits pour la GVHD ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme le méthotrexate et la ciclosporine sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "La thérapie cellulaire est-elle une option ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie cellulaire peut être explorée pour des cas réfractaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de la GVHD ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections, défaillance d'organes et cancers secondaires."
}
},
{
"@type": "Question",
"name": "La GVHD peut-elle entraîner des infections ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la GVHD affaiblit le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels cancers peuvent survenir après la GVHD ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers comme le lymphome et le carcinome peuvent se développer après la GVHD."
}
},
{
"@type": "Question",
"name": "La GVHD peut-elle affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes et complications peuvent gravement impacter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications de la GVHD ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut un suivi médical régulier et des traitements symptomatiques."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de la GVHD ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le sexe, et la compatibilité HLA entre donneur et receveur."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de GVHD ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients plus âgés ont un risque accru de développer la GVHD."
}
},
{
"@type": "Question",
"name": "Le sexe du receveur joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes peuvent avoir un risque plus élevé de GVHD que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies auto-immunes ou de greffes augmentent le risque."
}
},
{
"@type": "Question",
"name": "La source de greffe influence-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les greffes de moelle osseuse présentent un risque plus élevé que celles de sang de cordon."
}
}
]
}
]
}
Head and neck squamous cell carcinoma (HNSCC) negative for Human Papillomavirus (HPV) has remained a difficult to treat entity, whereas tumors positive for HPV are characterized by radiosensitivity an...
A tissue microarray of a single center HNSCC cohort was stained for ATM, DNA-PKcs and Ku80 and the expression scored based on staining intensity and the percentages of tumor cells stained. Scores were...
Samples from 427 HNSCC patients yielded interpretable stainings and were scored following an established algorithm. The majority of tumors showed strong expression of both NHEJ factors, whereas the ex...
Our data suggest that HPV-negative HNSCC with particularly low Ku80 expression represent a highly radiosensitive subpopulation. Confirmation in independent cohorts is required....
Gastric cancer is the fourth leading cause of cancer-related deaths in the world. The identification of gastric cancer subtypes related to recognizable microbial agents may play a pivotal role in the ...
Paraffin blocks of 682 cases of various types of gastric cancer from Tehran, South and North areas of Iran were collected. Twelve tissue microarray (TMA) blocks were constructed from these blocks. Loc...
Fourteen out of 682 cases (2.1%) of gastric adenocarcinoma were EBER-positive. EBER was positive in 8 out of 22 (36.4%) of medullary carcinomas and 6 out of 660 (0.9%) of non-medullary type, which was...
EBV-associated gastric adenocarcinoma has a low prevalence in Iran. This finding can be due to epidemiologic differences in risk factors and exposures, and the low number of gastric medullary carcinom...
Patient-derived organoids have emerged as a useful tool to model tumour heterogeneity. Scaling these complex culture models while enabling stratified analysis of different cellular sub-populations, ho...
Multiplex immunofluorescence (mIF) imaging can provide comprehensive quantitative and spatial information for multiple immune markers for tumour immunoprofiling. However, application at scale to clini...
Archived formalin-fixed and paraffin-embedded (FFPE) heart tissue from autopsied individuals represents an important resource for investigating the DNA methylation of heart tissue of deceased individu...
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies. Tissue microarrays (TMA) are an established method of high throughput biomarker interrogation in tissues but ...
The knowledge of the exact oxygen partial pressure in tissue is crucial for patient care and in the treatment of ischemic medical conditions. However, current methods to assess oxygen partial pressure...
Blood loss by hemorrhaging wounds accounts for over one-third of ∼5 million trauma fatalities worldwide every year. If not controlled in a timely manner, exsanguination can take lives within a few min...
Lung cancer is a fatal disease that kills approximately 85% of those diagnosed with it. In recent years, advances in medical imaging have greatly improved the acquisition, storage, and visualization o...
Develop a computer-aided diagnostic system to detect lung cancer early by segmenting tumor and non-tumor tissue on Tissue Micro Array Analysis (TMA) histopathological images....
The prototype computer-aided diagnostic system was developed to segment tumor areas, non-tumor areas, and fundus on TMA histopathological images....
The system achieved an average accuracy of 83.4% and an F-measurement of 84.4% in segmenting tumor and non-tumor tissue....
The computer-aided diagnostic system provides a second diagnostic opinion to specialists, allowing for more precise diagnoses and more appropriate treatments for lung cancer....
Serial assessment of the biomechanical properties of tissues can be used to aid the early detection and management of pathophysiological conditions, to track the evolution of lesions and to evaluate t...